Is Amdocs (DOX) Offering Opportunity After Recent Share Price Pullback To Around US$63

• Wondering whether Amdocs at around US$63 still offers value or if the recent pullback is a warning sign? This article walks through what the current price may be implying.
• Over the short term, the share price has seen a 5.2% decline over 7 days and a 5.9% decline over 30 days, adding to a 21.4% drop year to date and a 22.1% decline over the last year.
• These returns sit against a backdrop of ongoing attention on Amdocs as a key software provider to telecom and media companies, with investors regularly weighing its contract pipeline, sector sentiment and cash flow profile. While this article is not tied to any single news announcement, it is intended to give you a standing reference on how to think about the stock's value through different market cycles.
• On Simply Wall St's valuation checks, Amdocs scores 5 out of 6. Next, you will see how different valuation methods frame the current share price and then, at the end, a broader way to think about what valuation really tells you as an investor.

Find out why Amdocs's -22.1% return over the last year is lagging behind its peers.

Approach 1: Amdocs Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects the cash a business is expected to generate in the future and then discounts those cash flows back to today to estimate what the entire company might be worth now.

For Amdocs, the model used is a 2 Stage Free Cash Flow to Equity approach that relies on cash flow projections. The latest twelve month Free Cash Flow sits at about $758.0 million. Analysts provide explicit Free Cash Flow forecasts for the next few years, and Simply Wall St then extends these out to 10 years, with projected Free Cash Flow of $956.5 million by 2030 and intermediate annual estimates in between.

After discounting each of these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $131.53 per share. Compared with the recent share price around $63, this output suggests Amdocs trades at a 52.1% discount to that intrinsic value. On this model alone, the shares appear materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amdocs is undervalued by 52.1%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amdocs.

Approach 2: Amdocs Price vs Earnings

For profitable companies like Amdocs, the P/E ratio is a common way to gauge what investors are currently willing to pay for each dollar of earnings. It quickly links the share price to the business's current profit, which is often the anchor for many valuation discussions.

What counts as a "normal" or "fair" P/E tends to reflect the balance between how fast earnings are expected to grow and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk can justify a lower one.

Amdocs currently trades on a P/E of about 11.9x. This sits close to the peer group average of 11.7x and below the broader IT industry average of around 19.8x. Simply Wall St's Fair Ratio for Amdocs is 22.1x. This is a proprietary estimate of what the P/E might be given factors such as the company's earnings profile, industry, profit margins, market value and risk characteristics. Because it blends these company specific inputs, the Fair Ratio can be more tailored than a simple comparison with peers or the overall industry.

Set against the Fair Ratio, Amdocs' current P/E of 11.9x sits materially lower than 22.1x. This points to the stock being priced below that implied level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Amdocs Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are Simply Wall St's way for you to attach a clear story about Amdocs to the numbers by linking your view on its future revenue, earnings and margins to a financial forecast, an implied fair value and then a simple comparison with the current share price.

On the Community page, Narratives are designed to be easy to use. You can see how different stories about Amdocs, such as a more optimistic view with a fair value around US$105.00 or a more cautious view closer to US$70.84, translate directly into different fair values that you can compare with the latest market price when thinking about buying or selling.

Because Narratives on the platform update automatically when new information such as earnings, guidance changes or major news is added, you are not locked into a static view and can quickly see how your Amdocs story and its implied fair value shift as fresh data comes through.

Do you think there's more to the story for Amdocs? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com